Antonella Boglione
Research Subjects
Research Interests
Antonella Boglione has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Comandone
Department of Medical Oncology, San Giovanni Bosco Hospital, ASL Città di Torino, 10154 Turin, Italy
1 shared publication - Fausto Petrelli
Oncology Unit ASST Bergamo Ovest Treviglio Italy
1 shared publication - Tiziana Comandone
Italian Group of Rare Tumors, Corso Galileo Ferraris 54, 10129 Torino, Italy
1 shared publication
Latest Publications
- Open Access
A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma
Osteosarcomas (OSs) are a group of neoplasms originating from bone cells, usually presenting in three specific age groups: children, young adults, and the elderly. High-grade OS is an extremely malignant tumor mainly due to evolution into metastatic disease, usually in the lungs. Survival of these patients has improved since the 1980s thanks to close cooperation between oncologists, oncological surgeons and orthopedic surgeons. Unfortunately, no progress has been made in the last 30 years and new, more effective drugs are needed. This article reviews the biological and pharmacological basis of the treatment of OS. Models of clinical pharmacology of the active drugs, toxic effects and reasons for primary and secondary resistance to old and new drugs are discussed.
Open AccessA Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma
Osteosarcomas (OSs) are a group of neoplasms originating from bone cells, usually presenting in three specific age groups: children, young adults, and the elderly. High-grade OS is an extremely malignant tumor mainly due to evolution into metastatic disease, usually in the lungs. Survival of these patients has improved since the 1980s thanks to close cooperation between oncologists, oncological surgeons and orthopedic surgeons. Unfortunately, no progress has been made in the last 30 years and new, more effective drugs are needed. This article reviews the biological and pharmacological basis of the treatment of OS. Models of clinical pharmacology of the active drugs, toxic effects and reasons for primary and secondary resistance to old and new drugs are discussed.